Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anatara Lifesciences Ltd ( (AU:ANR) ) just unveiled an announcement.
Anatara Lifesciences has applied for quotation on the ASX of 2,360,426 new ordinary fully paid shares. The securities, issued on February 25, 2026 following the exercise or conversion of existing options or other convertible instruments, will increase the company’s quoted capital base and potentially enhance liquidity for shareholders.
The application formalises the admission of these additional shares to trading under the ANR code. This incremental expansion of the register may modestly broaden market participation in the stock and reflects the take-up of previously granted equity-linked securities by holders.
The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is an Australian-listed company in the life sciences sector. It is focused on developing healthcare-related products, with its ordinary fully paid shares traded on the Australian Securities Exchange under the ticker ANR.
Average Trading Volume: 573,922
Technical Sentiment Signal: Sell
Current Market Cap: A$3.45M
Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.